TransMedics Group, Inc. (TMDX) Comparison with companies in other sectors?

TransMedics Group, Inc. has a share price of 33.83M. You can analyze TransMedics Group, Inc. (TMDX) competitors across different market sectors through stock heatmaps.

What are TMDX's NET and operating margins?

TransMedics Group, Inc. (TMDX) operating margin is around 0.11, and net profit margin is approximately 0.10 as of the latest reports.

In what way does TMDX's earnings per share (EPS) trend reflect its financial momentum?

TransMedics Group, Inc. (TMDX) EPS is 1.42 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for TransMedics Group, Inc. is 76.14, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for TransMedics Group, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for TransMedics Group, Inc. like P/E which is 74.34, P/B which is 13.66, and PEG which is 2.04. Compare them with sector averages to evaluate if the stock is priced fairly.

TransMedics Group, Inc.

TMDX•NASDAQ

Healthcare

Medical - Devices

$108.12

$1.33(1.25%)

Fundamental Analysis of TransMedics Group, Inc. (TMDX)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$1.42

P/E Ratio

76.14

ROE

0.22%

Net Margin

0.10%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$3.66B

Shares OutstandingTotal number of shares issued

$33.83M

Book Value/ShareNet worth per share

$7.90

Revenue/ShareAnnual revenue per share

$14.48

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$1.42

Net MarginNet income as percentage of revenue

10.03%

Operating MarginOperating income as percentage of revenue

10.76%

ROEReturn on shareholders' equity

21.88%

ROAReturn on total assets

5.84%

ROCEReturn on capital employed

6.72%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-1.87

Cash/ShareCash and equivalents per share

$9.20

FCF YieldFree cash flow as percentage of market cap

-1.73%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for TMDXFinancial Ratios Analysis details for TMDX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for TMDXSector Benchmarking details for TMDX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for TransMedics Group, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of TransMedics Group, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account TransMedics Group, Inc.'s unique business strengths and challenges.

Key Financial Metrics for TransMedics Group, Inc.

For TransMedics Group, Inc., essential financial indicators include EPS 1.42, PE 76.14, and ROE 0.22. These key ratios reveal insights into TransMedics Group, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare TransMedics Group, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of TransMedics Group, Inc.

Metrics like Net Margin 10.03% and ROA 5.84% shed light on how well TransMedics Group, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether TransMedics Group, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of TransMedics Group, Inc.

Using ratios such as P/B Ratio 13.66 and PEG Ratio 2.04, investors can assess whether TransMedics Group, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with TransMedics Group, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for TransMedics Group, Inc.

Financial health indicators, such as Debt/Equity Ratio 1.95 and Cash Flow $-1.87, provide a snapshot of TransMedics Group, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like TransMedics Group, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for TransMedics Group, Inc.

Investing in TransMedics Group, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at TransMedics Group, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;